Hengrui Medicine announces share repurchase progress

Jiangsu Hengrui Medicine (SSE:600276) announced progress in its share repurchase program, revealing that by February 28, 2025, the company had repurchased 5,530,044 shares, representing 0.09% of the total share capital. The purchases were made through centralized bidding transactions, with prices ranging from a high of 57.01 RMB per share to a low of 39.00 RMB per share. The total expenditure for the repurchase amounted to 233,902,752.60 RMB (approximately $32,486,000 USD), excluding transaction costs. This repurchase is in line with the previously disclosed plan, which was approved on May 15, 2024, for employee stock ownership. The company stated it will continue to make repurchase decisions based on market conditions and will disclose further developments in a timely manner.